

ETNA-VTE Europe: The Effect of Body Mass Index on 12-Month Outcomes in VTE Patients with Edoxaban

Marc Schindewolf¹, Bernd Brüggengjürgen², Cihan Ay³, Philippe Hainaut⁴, Ulrich Hoffmann⁵, Sean Gaine⁶, Michiel Coppens⁷, David Jiménez⁸, Pierre Levy⁹, Julio Lopez Bastida¹⁰, Eric Vicaut¹¹, Peter Bramlage¹², Giancarlo Agnelli¹³, Alexander T. Cohen¹⁴, and on behalf of the ETNA-VTE-Europe investigators

¹Swiss Cardiovascular Centre, Division of Angiology, University of Bern, Bern University Hospital, Switzerland; ²Institute for Health Economics, Steinbeis-University, Berlin, Germany; ³Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria; ⁴Department of General Internal Medicine, Cliniques Universitaires Saint Luc, UCL, Bruxelles, Belgium; ⁵Division of Angiology, Medical Clinic IV, University Hospital, Ludwig-Maximilians-University, Munich, Germany; ⁶National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland; ⁷Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands; ⁸Respiratory Department, Ramón y Cajal Hospital, Madrid, Spain; ⁹LEGOS, Université Paris – Dauphine, Paris, France; ¹⁰University of Castilla-La Mancha, Talavera de la Reina, Toledo, Spain; ¹¹Department of Medicine, Université Paris Descartes, Paris, France; ¹²Institute for Pharmacology and Preventive Medicine, Berlin, Germany; ¹³Internal and Cardiovascular Medicine-Stroke Unit, University of Perugia, Perugia, Italy; ¹⁴Guy's and St Thomas' NHS Foundation Trust, King's College London, London, UK

Introduction

- Venous thromboembolism (VTE) is the third most common cardiovascular disease, affecting about 10 million people globally each year¹
- Edoxaban, a non-vitamin K antagonist oral anticoagulant (NOAC), is approved for the treatment and secondary prevention of acute VTE in adults based on its comparable efficacy and superior safety to warfarin in a broad spectrum of patients with VTE during the Hokusai-VTE trial²
- During the treatment of VTE, obesity may affect the bioavailability, distribution and half-life of NOACs and, consequently, outcomes of treatment³
- Dose reduction of edoxaban is recommended in patients with one or more of the following clinical factors: moderate or severe renal impairment (creatinine clearance 15–50 mL/min), body weight ≤60 kg, concomitant use of certain P-glycoprotein inhibitors⁴
- ETNA-VTE-Europe (NCT02943993) was initiated in agreement with the European Medicines Agency (EMA) to assess benefits and risks of edoxaban treatment and secondary prevention of VTE with edoxaban up to 18 months in routine clinical practice⁵

Aim

- Using data from the ETNA-VTE-Europe registry, our aim was to characterise obese patients and to investigate outcomes in patients treated with edoxaban categorised by BMI

Methods

- ETNA-VTE-Europe is a single-arm, multinational, prospective, non-interventional post-authorisation safety study conducted in 310 sites in 8 European countries (NCT02943993)⁵
- A total of 2,322 patients with acute VTE treated with edoxaban were enrolled, and will be followed-up for 18 months subsequent to the index VTE
- The primary objective of ETNA-VTE-Europe was to assess the 18-month rate of symptomatic VTE recurrence in patients with VTE treated with edoxaban in clinical practice
- The co-primary objective was to assess the real-world rates of bleeding and adverse drug reactions
- This sub-study analysed outcomes in normal weight (BMI 18.5–25 kg/m²), overweight (BMI 25–30 kg/m²) and obese (BMI >30 kg/m²) patients enrolled into the ETNA-VTE-Europe study
- Results for patients with BMI ≤18.5 kg/m² are not reported due to low patient numbers in this subgroup (n=18) and 149 patient had missing BMI data
- Patients with history of cancer, active cancer at baseline or new cancer within 6 months (182 days) after start of acute index VTE were excluded from the analysis to avoid confounding factors

Results


- This snapshot analysis set included 2131 patients who completed 1-year follow-up
- Of these patients, 573 were normal weight, 849 were overweight and 560 were obese (Table 1)
- Obese patients were more often female, had higher rates of hypertension, diabetes and prior VTE, chronic venous insufficiency and a higher eGFR than non-obese patients (Table 1)
- Obese patients received the 60 mg edoxaban dose more often (Table 1)
- At 1-year follow-up, overall VTE recurrence was 2.67% with consistent results across the range of BMI categories (Figure 1)
- Any bleeding was observed in 12.29% and major bleeding in 1.69% with a numerical decrease in obese patients (Figure 2)
- While all-cause mortality followed a U-shape association across BMI groups, there was a consistent trend for a reduced cardiovascular mortality in obese patients (Figure 3)

Table 1. Patient characteristics by BMI category

Patient characteristics	Overall** (N=2131)	BMI 18.5 to <25 kg/m ² * (N=573)	BMI 25 to <30 kg/m ² * (N=849)	BMI ≥30 kg/m ² * (N=560)
Female, n (%)	983 (46.1)	297 (51.8)	335 (39.5)	322 (51.3)
Age, years, mean ± SD	62.4 ± 16.07	61.9 ± 18.19	64.0 ± 14.93	61.9 ± 14.97
BMI, kg/m ² , mean ± SD	27.9 ± 5.00	22.7 ± 1.85	27.3 ± 1.37	34.2 ± 4.04
recalc. eGFR (Cockcroft-Gault), ml/min, mean ± SD	95.7 ± 38.95	82.1 ± 31.85	92.3 ± 34.60	114.0 ± 44.88
Frailty (physician judgement), n (%)	261 (12.2)	75 (13.1)	106 (12.5)	75 (11.9)
Medical history, n (%)				
Hypertension	888 (41.7)	165 (28.8)	359 (42.3)	360 (57.3)
Diabetes mellitus	235 (11.0)	40 (7.0)	81 (9.5)	117 (18.6)
Chronic venous insufficiency	234 (11.0)	49 (8.6)	104 (12.2)	85 (13.5)
Bleeding history	60 (2.8)	20 (3.5)	21 (2.5)	18 (2.9)
Ischaemic stroke	52 (2.4)	14 (2.4)	22 (2.6)	15 (2.4)
History of VTE, n (%)				
Prior PE±DVT	160 (7.5)	38 (6.6)	55 (6.5)	54 (8.6)
Prior DVT	350 (16.4)	89 (15.5)	149 (17.6)	108 (17.2)
Edoxaban treatment at baseline, n (%)				
Edoxaban 60 mg	1873 (87.9)	449 (78.4)	771 (90.8)	521 (93.0)
Edoxaban 30 mg	258 (12.1)	124 (21.6)	78 (9.2)	39 (7.0)


*Patients with history of cancer, active cancer at baseline or new cancer within 6 months (182 days) after start of acute index VTE were excluded from the analysis; †One hundred and forty-nine patients had missing BMI. DVT, deep vein thrombosis; eGFR, estimated glomerular filtration rate; PE, pulmonary embolism; SD, standard deviation; VTE, venous thromboembolism

Figure 1. Annualised efficacy event rates by BMI category




*A total of 149 patients had missing BMI
†Patients with history of cancer, active cancer at baseline or new cancer within 6 months (182 days) after start of acute index VTE were excluded from analysis; DVT, deep vein thrombosis; GI, gastrointestinal; PE, pulmonary embolism; SE, systemic embolism; VTE, venous thromboembolism; SEE, systemic embolic events

Figure 2. Annualised safety event rates by BMI category



*A total of 149 patients had missing BMI
†Patients with history of cancer, active cancer at baseline or new cancer within 6 months (182 days) after start of acute index VTE were excluded from analysis; CRNM, clinically relevant non-major; GI, gastrointestinal; ICH, intracranial haemorrhage; ISTH, International Society on Thrombosis and Haemostasis

Figure 3. Annualised mortality event rates by BMI category



*A total of 149 patients had missing BMI
†Patients with history of cancer, active cancer at baseline or new cancer within 6 months (182 days) after start of acute index VTE were excluded from analysis; CV, cardiovascular

Conclusions

- Obesity does not appear to substantially affect the risks of recurrent VTE and any bleeding complications in a contemporary cohort of edoxaban-treated patients
- Apart from all-cause mortality following a U-shape association and CV mortality being numerically lowest in BMI ≥30, which may be due to chance, there were no appreciable differences in outcomes across the various subgroups

References

- Di Nisio M, et al. *Lancet*. 2016;388:3060-73
- Büller HR, et al. *N Engl J Med*. 2013;369:1406-15
- Steffel J, et al. *Eur Heart J*. 2018;39:1330-93
- Edoxaban SmPC. 2020
- Cohen AT, et al. *Thromb J*. 2018;16:9

Acknowledgements

This poster was sponsored by Daiichi Sankyo Europe GmbH, Munich, Germany. Writing and editorial support were provided by Sean Littlewood from inScience Communications, Springer Healthcare Ltd, UK and funded by Daiichi Sankyo Europe GmbH, Munich Germany

Disclosure

Marc Schindewolf has received speaker fees from Abbott, Aspen, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, GlaxoSmithKline and Sanofi; travel grants from Bard, Bayer, Bristol-Myers Squibb, Medtronic and Terumo; research grants from Cook, Daiichi Sankyo and Terumo; and consulting fees from Bayer, Bristol-Myers Squibb, Daiichi Sankyo and Sanofi

ETNA-VTE
Europe